

15. (amended) A process for the manufacture of the salt as defined in any one of claims 1 to 3 or 18 characterized by the following consecutive steps:

- Feb 03/
- i) dissolving (R)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide in an appropriate solvent, optionally by heating,
 - ii) adding (2*R*,3*R*)-tartaric acid[, respectively,] dissolved in an appropriate aqueous organic solvent or non-aqueous organic solvent,
 - iii) allowing the solution obtained to stand cold to crystallize,
 - iv) optionally recrystallizing in an appropriate aqueous organic solvent, if a non-aqueous organic solvent is used in step ii), to obtain the salt defined in [any one of claims 2 or 3] claim 2 or 18.

16. (amended) A process for the manufacture of the salt as defined in [claims 2 to 3] claim 2 or 18 characterized by recrystallizing (R)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-benzopyran-5-carboxamide hydrogen (2*R*,3*R*)-tartrate in an appropriate aqueous organic solvent.

Feb 03/ 17. (amended) A process according to [any one of the] claim[s] 15 or 16, wherein the aqueous organic solvent is aqueous acetone.

Add the following new claims:

- 12 Sub 24*
- 18. The salt according to claim 2 in substantially crystalline form.
- 19. A method according to claim 12 for the prevention or the treatment of urinary incontinence.--